XNK Therapeutics AB (“XNK”) announces its collaboration agreement with Israel-based Cellect Biotechnology (“Cellect”) to develop the next generation version of XNK’s innovative technology…
XNK Therapeutics AB (“XNK”) today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its leading investigational drug candidate in the…
The extraordinary general meeting in XNK Therapeutics AB (“the Company”) was held on October 14, 2020, where the general meeting resolved in accordance with submitted proposals. The following…
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Stephan Meinke as Head of R&D Dr. Meinke received his doctorate degree in 2010 from the University of Heidelberg, Germany,…
Today results from the first-in-human study ACP-001 was made public at the 2020 EHA meeting. Key findings from the study: Overall survival (OS) 100% after a median follow-up time of 60 months…
XNK Therapeutics AB (“XNK”) today announced the appointment of Hans Ericson as Chief Financial Officer Hans Ericson is a senior finance professional with more than 20 years’ experience in…
XNK Therapeutics AB (“XNK”) today announced its appointment of Johan Liwing as CEO of the company and prepares for the next phase of development of its technology platform and leading drug…
XNK Therapeutics AB (“XNK”) today announced it joined Sweden’s Innovation Agency’s NextGenNK competence center for the development of next-generation natural killer (NK) cell-based cancer…
